BTAI Logo

BioXcel Therapeutics, Inc. (BTAI) 

NASDAQ
Market Cap
$23.87M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
585 of 966
Rank in Industry
318 of 554

Largest Insider Buys in Sector

BTAI Stock Price History Chart

BTAI Stock Performance

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Insider Activity of BioXcel Therapeutics, Inc.

Over the last 12 months, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $455,502 worth of BioXcel Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $34.4M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,108 shares for transaction amount of $14,514 was made by MUELLER PETER (director) on 2019‑08‑23.

List of Insider Buy and Sell Transactions, BioXcel Therapeutics, Inc.

2024-10-03SaleChief Scientific Officer
7,175
0.0181%
$0.55$3,946+3.08%
2024-10-03SaleSee Remarks
6,863
0.0173%
$0.55$3,775+3.08%
2024-10-03SaleChief Financial Officer
7,175
0.0181%
$0.55$3,946+3.08%
2024-10-03SaleSee Remarks
5,556
0.014%
$0.55$3,056+3.08%
2024-10-03SaleChief Commercial Officer
6,272
0.0158%
$0.55$3,450+3.08%
2024-09-16SaleCEO and President
1,982
0.0052%
$0.69$1,367-11.02%
2024-09-16SaleChief Scientific Officer
355
0.0009%
$0.69$245-11.02%
2024-09-16SaleSee Remarks
345
0.0009%
$0.69$238-11.02%
2024-09-16SaleChief Financial Officer
356
0.0009%
$0.69$246-11.02%
2024-09-16SaleChief Commercial Officer
215
0.0006%
$0.69$149-11.02%
2024-09-16SaleSee Remarks
138
0.0004%
$0.69$95-11.02%
2024-06-17SaleCEO and President
2,134
0.0051%
$1.28$2,739-52.24%
2024-06-17SaleChief Scientific Officer
372
0.0009%
$1.28$476-52.24%
2024-06-17SaleSee Remarks
361
0.0008%
$1.26$456-52.24%
2024-06-17SaleChief Financial Officer
372
0.0009%
$1.26$470-52.24%
2024-06-17SaleSee Remarks
155
0.0004%
$1.28$199-52.24%
2024-06-17SaleChief Commercial Officer
244
0.0006%
$1.26$308-52.24%
2024-06-05SaleCEO and President
409,136
0.3263%
$0.49$199,619-59.94%
2024-06-04SaleCEO and President
1.02M
0.3359%
$0.20$205,516-60.21%
2024-04-04SaleCEO and President
5,268
0.0153%
$2.62$13,823-65.96%

Insider Historical Profitability

94.37%
Mehta VimalCEO and President
51666
0.1069%
$0.49911+91.12%
Yocca FrankChief Scientific Officer
28278
0.0585%
$0.4959+91.88%
Rodriguez JavierSee Remarks
23770
0.0492%
$0.4906
Steinhart Richard IChief Financial Officer
20279
0.0419%
$0.4937+87.62%
O'Neill VincentSee Remarks
19601
0.0405%
$0.4909
Wiley Matthew T.Chief Commercial Officer
19011
0.0393%
$0.4904
BioXcel LLC10 percent owner
8546750
17.6774%
$0.4901
BioXcel Holdings, Inc.10 percent owner
8546750
17.6774%
$0.4901
MUELLER PETERdirector
168320
0.3481%
$0.4960+104.84%
Nandabalan Krishnan
0
0%
$0.4915+93.45%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$7.03M6.652.49M-0.97%-$68,943.36<0.0001
BlackRock$3.75M3.541.33M-3.36%-$130,137.36<0.0001
The Vanguard Group$3.1M2.931.1M+0.91%+$27,951.83<0.0001
Ameriprise Financial$1.63M1.54579,164+7.04%+$107,442.03<0.0001
State Street$1.31M1.24464,908+5.58%+$69,304.34<0.0001
Geode Capital Management$1.29M1.22457,920+1.71%+$21,696.77<0.0001
Armistice Capital Llc$1.05M0.99370,973New+$1.05M<0.01
Beacon Pointe Advisors Llc$850,893.000.8301,7350%+$00.01
Morgan Stanley$626,883.000.59222,299+15.93%+$86,136.88<0.0001
Northern Trust$596,717.000.56211,602-6.12%-$38,879.30<0.0001
Charles Schwab$538,535.000.51190,970+1.84%+$9,757.19<0.0001
UBS$414,983.000.39147,157+204.55%+$278,720.52<0.0001
BNY Mellon$347,077.000.33123,077-2.71%-$9,669.78<0.0001
Wells Fargo$347,103.000.33123,086+58.15%+$127,624.92<0.0001
Castleview Partners LLC$274,326.000.2697,279New+$274,326.000.18
Susquehanna International Group$254,336.000.2490,190New+$254,336.00<0.0001
Pennant Capital Management Llc$236,598.000.2283,9000%+$00.04
Tocqueville Asset Management$136,065.000.1348,250-3.98%-$5,640.00<0.01
Federated Hermes$135,098.000.1347,907New+$135,098.00<0.0001
Bank of America$133,578.000.1347,368-54.6%-$160,630.31<0.0001
Millennium Management LLC$127,250.000.1245,124-48.69%-$120,772.44<0.0001
Bank of Montreal$120,008.000.1142,108-5.38%-$6,817.21<0.0001
Citadel Advisors LLC$114,613.000.1140,643+662.53%+$99,582.43<0.0001
Thrivent Financial For Lutherans$113,000.000.1140,0000%+$0<0.0001
Cambridge Investment Research Advisors Inc$107,000.000.138,0500%+$0<0.0001
Davenport & Company$96,966.000.0934,385-2.83%-$2,820.01<0.01
Xtx Topco Ltd$88,018.000.0831,212New+$88,018.00<0.01
AllianceBernstein$84,572.000.0829,9900%+$0<0.0001
Atom Investors Lp$84,081.000.0829,816New+$84,081.000.01
RhumbLine Advisers$83,703.000.0829,685+2.42%+$1,976.62<0.0001
Renaissance Technologies$67,000.000.0623,707New+$67,000.00<0.0001
Goldman Sachs$64,211.000.0622,770+18.59%+$10,067.34<0.0001
Invesco$53,131.000.0518,841+33.14%+$13,225.65<0.0001
Raymond James Associates$52,257.000.0518,531-2.21%-$1,178.75<0.0001
U.S. Bancorp$50,853.000.0518,0330%+$0<0.0001
Capital Investment Advisory Services Llc$50,267.000.0517,8250%+$00.01
Deutsche Bank$49,454.000.0517,5370%+$0<0.0001
SeaCrest Investment Management, LLC$48,645.000.0517,250-4.96%-$2,538.000.01
Barclays$41,000.000.0414,772-47.04%-$36,423.17<0.0001
Simplex Trading Llc$40,000.000.0414,321New+$40,000.00<0.01
Virtu Financial Llc$39,000.000.0413,990-76.49%-$126,907.51<0.01
Creative Planning$37,292.000.0413,224-34.61%-$19,740.17<0.0001
BB&T$30,679.000.0310,8790%+$0<0.0001
Apollon Wealth Management, LLC$28,679.000.0310,170-3.48%-$1,034.93<0.01
American International Group$29,088.000.0310,315+2.3%+$654.23<0.0001
JPMorgan Chase$25,199.000.028,936-29.65%-$10,622.72<0.0001
Zurich Cantonal Bank$21,550.000.027,642-3.19%-$710.63<0.0001
Tower Research Capital$13,048.000.014,627-66.55%-$25,957.82<0.0001
AllSquare Wealth Management, LLC$12,766.000.014,5270%+$00.01
Citigroup$9,912.000.013,515+21.63%+$1,762.45<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.